A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/- radiotherapy in adults with recurrent or newly diagnosed glioblastoma


BACKGROUND

Glioblastoma (GBM)

- GBM is the most aggressive and common type of cancer originating in the brain
- Patients (pts) with GBM have a very poor prognosis for survival1,2
- GBM tumors can be difficult to target due to their fast-growing nature and the blood-brain-barrier which creates an obstacle to available treatments3
- Newly diagnosed GBM treatment is typically multi-faceted, including surgery and chem-/or radiotherapy4,5; however, even with best standard-of-care (SOC), recurrence is often inevitable and effective treatment options are limited6

WEE1 kinase

- WEE1 kinase, a key regulator of the S phase and G2M cell cycle checkpoints, activates the DNA damage response (DDR) pathway before mitotic entry4
- The DDR pathway is often upregulated in cancer cells due to genomic instability, leading to resistance to DNA-damaging therapies7
- Blocking DNA repair pathways via checkpoint kinase inhibition renders cells more vulnerable to DNA damage-inducing therapies8

Wee1 inhibition and glioblastoma

- WEE1 inhibition leads to S phase and G2/M abrogation, permitting mitosis without DNA repair, leading to mitotic catastrophe and subsequent cell death9

Debio 0123

- Debio 0123 is an oral, brain-penetrant, highly selective, small-molecule WEE1 inhibitor10
- Preclinically, Debio 0123 has been shown to effectively penetrate the brain and WEE1 target engagement has been observed in early-phase clinical trials11

Debio 0123 demonstration of improved response to radiotherapy (RT) in vitro and to temozolomide (TMZ) in mouse models of GBM, supporting clinical investigation of Debio 0123 in combination with TMZ12,13

STUDY DESIGN

We present the design of a Phase 1/2, intervention-al, non-randomized, open-label, multicenter study of Debio 0123 in pts with recurrent and newly diagnosed GBM

- A Bayesian logistic regression model-based decision is being used to guide the dose escalation for both Phase 1 Arm A and Arm B

This two-part study, initiated in March 2023, is registered as NCT07565812

Phase 1 Arm A

- Assessing Debio 0123 with TMZ-based chemotherapy to identify the recommended Phase 2 dose (RP2D) of Debio 0123
- Dose-limiting toxicity (DLT)-evaluable pts with either recurrent or progressive GBM iso- or dehydrogenase (IDH-wildtype) (WT), Grade 4 (per WHO 2021 criteria)14 or astrocytoma, IDH-mutant, Grade 3 (per WHO 2021 criteria)14 will be enrolled, receiving escalating doses of Debio 0123 in TMZ in 28-day cycles, as capsules

Phase 1 Arm B

- Assessing debio 0123 with concomitant TMZ and RT to identify the RP2D of Debio 0123
- DLT- evaluable pts with newly diagnosed GBM IDH-WT, Grade 4 will be enrolled, receiving escalating doses of concomitant TMZ and RT for 6 weeks
- Radiotherapy will be administered in accordance with the local clinical practice and RTOG or EORTC guidelines15

Phase 2: assessing the efficacy of the Phase 1 Arm A RP2D of Debio 0123

- Externally controlled, open-label study comparing the efficacy of Debio 0123 with TMZ at the RP2D of Phase 1 Arm A vs SOC in pts with recurrent GBM IDH-WT
- Up to 41 pts with recurrent or progressive GBM IDH-WT Grade 4 after first-line concurrent TMZ-RT will be evaluated per arm
- Pts in the experimental arm will receive Debio 0123 at the RP2D of Phase 1 Arm A and TMZ in each 28-day cycle for up to 2 years
- The external control arm includes data from pts treated with SOC therapy from recently completed historical clinical trials (HCTs)
- Propensity score methods will be used to balance baseline and disease-specific prognostic factors of external control arm pts to pts receiving Debio 0123

SUMMARY

- WEE1 kinase, a key regulator of cell cycle progression and DDR pathway activation, is often upregulated in tumor cells and therefore represents an interesting therapeutic target for cancers
- Debio 0123 is a brain-penetrant, highly-selective WEE1 inhibitor that has been shown to improve response to RT in vitro and to TMZ in mouse models
- Phase 1 of this study will identify the RP2D of Debio 0123 in combination with TMZ +/-RT and Phase 2 will assess the safety and efficacy of the RP2D established in Phase 1 Arm A in pts with recurrent, progressive GBM
- The study is ongoing and enrolling pts in the US, Spain and Switzerland

STUDY OBJECTIVES

ELIGIBILITY

Phase 1 Arm A and Phase 2

- Age ≥18 years old
- Measurable or non-measurable disease as per RANO criteria by gadolinium (Gd)-based contrast-enhanced brain magnetic resonance imaging (MRI)
- Pts receiving corticosteroids must be on stable or decreasing dose of ≤4 mg daily
- Measurable or non-measurable disease as per RANO criteria by gadolinium (Gd)-based contrast-enhanced brain magnetic resonance imaging (MRI)
- Karnofsky Performance Status (KPS) ≥60

KEY INCLUSION CRITERIA

Phase 1 Arm A

- Histopathologically proven diagnoses of either: GBM, IDH-wildtype, Grade 4 (per WHO 2021)14 may include secondary GBMs (i.e., progression from low-grade gliomas) or astrocytoma, IDH-mutant, Grade 3 (per WHO 2021)1

Phase 1 Arm B

- New, histopathologically proven diagnoses of GBM, IDH-WT Grade 4 (per WHO 2021)14 may include secondary GBMs (i.e., progression from low-grade gliomas)

KEY EXCLUSION CRITERIA

Phase 1 Arm A and Phase 2

- Prior treatment with >2 lines of therapy for GBM IDH-wildtype, Grade 4, or for astrocytoma, IDH-mutant, Grade 3
- Prior treatment with ≥2 lines of therapy for GBM IDH-wildtype, Grade 4, or for astrocytoma, IDH-mutant, Grade 3
- Prior radiation, chemotherapy, biological therapy, interstitial brachytherapy, implanted chemotherapy, therapeutics delivered by local injection or convection-enhanced delivery for GBM

Phase 2

- Prior treatment with ≥1 line of systemic therapy for GBM IDH-wildtype, Grade 4, Combination therapy with TMZ and RT with/without subsequent TMZ treatment is considered as ≥1 line

REFERENCES

5. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of the Central Nervous System 2017

ABBREVIATIONS

CCDG: cell division control 2; CHK2: checkpoint kinase 2; CDD: chemotheraputic agents; DOR: DNA damage response; DLT: dose-limiting toxicity; ECG: electrocardiogram; EORTC: European Organisation for Research and Treatment of Cancer; GBM: glioblastoma, IDH-wildtype, gadolinium-based, HCT: historical clinical trials; IDH-WT: isocitrate dehydrogenase-wildtype; KPS: Karnofsky Performance Score; MRI: magnetic resonance imaging; OR: objective response; pts: patients; RANO: Response Assessment in Neuro-Oncology; RP2D: recommended Phase 2 dose; RT: radiotherapy; RTOG: Radiation Therapy Oncology Group; SOC: standard of care; TAE: treatment-emergent adverse event; TMZ: temozolomide; WHO: World Health Organisation; VEGF: vascular endothelial growth factor

STUDY CONTACT

Victor.RodriguezFreixinos@debiopharm.com

CONFLICTS OF INTEREST

This study is funded by Debiopharm International SA. Authors would like to thank all patients, family members and each Debio-0123-105 clinical study member for their dedication and collaboration.

ACKNOWLEDGEMENTS

This study is funded by Debiopharm International SA. We would like to thank all patients, family members and each Debio-0123-105 clinical study member for their dedication and collaboration.

[ABSTRACT: RTID-03]